<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0001903'>anemia</z:hpo> responds to recombinant human erythropoietin (rHuEPO) alone and in combination with recombinant human granulocyte-colony-stimulating factor (rHuGCSF) in 10% to 20% and in 35% to 40% of patients, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>We randomly divided 60 patients with low-grade anemic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and serum EPO levels lower than 500 IU/L (500 mU/mL) into 2 groups: rHuEPO + rHuG-CSF (arm A) and supportive care (arm B) </plain></SENT>
<SENT sid="2" pm="."><plain>After 12 weeks, those who had erythroid responses were given rHuEPO alone for 40 additional weeks </plain></SENT>
<SENT sid="3" pm="."><plain>They were also given rHuG-CSF if they had relapses </plain></SENT>
<SENT sid="4" pm="."><plain>A response was considered major if the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (Hb) level was 115 g/L (11.5 g/dL) or higher and minor Hb increase was 15 g/L (1.5 g/dL) or more or if it remained stable without transfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Ten of 24 patients responded in arm A, and 0 of 26 responded in arm B (P =.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Eight patients in arm A continued rHuEPO therapy alone, and 6 had relapses </plain></SENT>
<SENT sid="7" pm="."><plain>Responses were always restored when rHuG-CSF was reintroduced </plain></SENT>
<SENT sid="8" pm="."><plain>Mean direct costs per patient were 26,723 euros (arm A) and 8,746 euros (arm B) </plain></SENT>
<SENT sid="9" pm="."><plain>Quality of life was assessed with a Functional Assessment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Therapy-<z:hpo ids='HP_0001903'>Anemia</z:hpo> (FACT-An) scale </plain></SENT>
<SENT sid="10" pm="."><plain>Similar percentages of patients from both arms showed significant clinical improvement </plain></SENT>
<SENT sid="11" pm="."><plain>rHuEPO plus rHuG-CSF led to responses in 41.7% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="12" pm="."><plain>This treatment was expensive </plain></SENT>
<SENT sid="13" pm="."><plain>No effect on quality of life was demonstrated </plain></SENT>
</text></document>